Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0721-8060 · 1 trial · 2 indications
Measured as number of events.
Measured as number of events.
Measured as percentage change in body weight.
| Arm | Type | Description |
|---|---|---|
| NNC0721-8060 | EXPERIMENTAL | Participants will receive subcutaneous injection of NNC0721-8060. |
| Semaglutide | ACTIVE_COMPARATOR | Participants will receive subcutaneous injection of semaglutide. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive subcutaneous injection of placebo. |
| Name | Type | Description |
|---|---|---|
| NNC0721-8060 | DRUG | NNC0721-8060 will be administered subcutaneously. |
| Semaglutide | DRUG | Semaglutide will be administered subcutaneously. |
| Placebo | DRUG | Placebo will be administered subcutaneously. |
Inclusion Criteria: * Male or female (sex at birth). * Age 18-55 years (both inclusive) at the time of signing informed consent. * Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the invest...
NNC0721-8060 is an investigational small molecule being developed for the treatment of overweight and obesity. It is currently in Phase 1 clinical development, with a first-in-human study recruiting participants who are overweight or have obesity.
NNC0721-8060 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker symbol NVO. The company is conducting a Phase 1 clinical trial to evaluate the drug in people with overweight or obesity.
NNC0721-8060 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A first-in-human study is currently recruiting participants in the United States to evaluate its safety and how it works.
NNC0721-8060 is being studied in a Phase 1 clinical trial with the identifier NCT07767175. This first-in-human study is recruiting 142 participants who are overweight or have obesity, and it is being conducted at sites in the United States.
Yes, NNC0721-8060 is a small molecule drug. It is being developed as an oral or injectable medication for the treatment of overweight and obesity, and it is currently in early-stage clinical testing.